Smartphone monitoring, quantitative orbital imaging and clinical data will support a planned longitudinal study and a TORC-led research database.
SEOUL, South Korea, Nov. 17, 2026 /PRNewswire/ — Thyroscope (THYROSCOPE INC.) and The Orbital Radiology Center (TORC) today announced a memorandum of understanding to investigate an integrated approach to monitoring thyroid eye disease (TED) using smartphone-based artificial intelligence, quantitative orbital imaging and longitudinal clinical data.
Thyroscope will contribute its Glandy smartphone-based AI platform for monitoring patients between clinical visits, while TORC will provide quantitative orbital imaging expertise. Together, the partners will develop a multimodal TED research database integrating smartphone-based assessments, quantitative imaging and longitudinal clinical data. BioSight Innovations, also led by TORC CEO Dr. Shoaib Ugradar, will provide treatment sites, clinical assessments and longitudinal follow-up for the initial study.
TORC has provided contracted imaging assessment services for four clinical trials sponsored by Viridian Therapeutics, Zenas BioPharma, Lassen Therapeutics and Immunovant, and for an Amgen post-marketing study. Its scientific work includes nine published papers on quantitative imaging in TED.

Figure 1. Proposed multimodal TED research workflow. Glandy phone is from Thyroscope materials; CT and audiometry visuals are illustrative.
Why Better Monitoring Matters
TED is an autoimmune disease that can cause inflammation, proptosis, eyelid retraction, double vision and, in severe cases, irreversible vision loss. Despite expanding treatments, assessment still relies on scheduled clinic visits. Measurements such as proptosis and the Clinical Activity Score (CAS) may vary between assessors and do not fully capture changes within orbital tissues.
The partners will study whether home measurements and imaging improve longitudinal assessment.
Combining Complementary Technologies
Thyroscope’s Glandy TED suite uses smartphone images and patient-reported information to assess inflammatory activity (Glandy CAS), proptosis (Glandy EXO) and eyelid morphology (Glandy LID). Its clinician-facing Glandoc platform makes patient-generated information available for review between appointments. All three Glandy TED solutions have obtained medical device authorization in South Korea and CE marking under the European Medical Device Regulation (EU MDR).
TORC analyzes orbital CT and MRI, clinical photographs and associated clinical data to quantify tissue morphology and volumetric change. Its imaging capabilities complement the more frequent external measurements that patients may collect at home.
BioSight Innovations will provide the clinical infrastructure for treatment and longitudinal follow-up, including conventional pure-tone audiometry using SHOEBOX Audiometry.
Initial 40-Patient Research Study
The partners plan to begin a prospective longitudinal feasibility and validation study of approximately 40 patients receiving TED treatment at BioSight Innovations centers in Los Angeles in January 2027. Participants will be followed from treatment initiation until up to 12 months after treatment completion.
The study will compare smartphone-derived assessments with clinician-performed measurements and examine relationships with quantitative orbital imaging where CT or MRI is clinically appropriate and available. It will explore changes in disease activity, proptosis, eyelid position, anatomical findings, treatment response and clinically confirmed recurrence.
All participants will undergo conventional audiometry at BioSight using SHOEBOX Audiometry. These measurements will inform iterative development and evaluation of an investigational smartphone-based pure-tone hearing assessment integrated into Glandy. The study will assess agreement, distinguishing development from independent validation. The smartphone test is not intended to replace conventional audiometry.
The initial study is designed to establish feasibility and measurement agreement, not to validate recurrence prediction or treatment-selection algorithms. Interim findings are targeted for the first quarter of 2028, depending on enrollment and data availability.
Building a Multimodal TED Research Database
TORC and Thyroscope plan to jointly develop a longitudinal, multimodal TED research database integrating orbital imaging, smartphone-based assessments, standardized clinical findings, treatment exposures, outcomes and audiometric data. Future phases may incorporate consented tissue-derived and molecular information and larger patient cohorts.
The longer-term goal is to support studies of treatment response, disease recurrence, imaging biomarkers and potential predictors of therapeutic benefit.
Subject to scientific validation and appropriate data governance, the resource could also support pharmaceutical research into reproducible clinical trial endpoints and patient stratification.
Leadership Perspectives
DR. SHOAIB UGRADAR
CEO, TORC
“Thyroid eye disease is entering a new era of targeted therapeutics, yet our ability to objectively characterize treatment response and predict recurrence remains limited,” said Dr. Shoaib Ugradar, CEO of TORC. “By combining quantitative orbital imaging with measurements collected between visits, we hope to better understand how patients respond, why some relapse and how more personalized care might eventually be supported.”
JAEMY PARK
CEO, Thyroscope
“Combining Glandy’s smartphone-based assessments with TORC’s imaging expertise creates an opportunity to study thyroid eye disease more continuously,” said Jaemy Park, CEO of Thyroscope. “We aim to make objective measurement more accessible while contributing patient-generated information to rigorous longitudinal research.”
About the Organizations
Thyroscope is a South Korean medical technology company developing AI-based assessment and monitoring technologies for thyroid disorders. Its Glandy TED portfolio includes smartphone-based tools for disease activity, proptosis and eyelid assessment. Learn more at www.thyroscope.com/en.
The Orbital Radiology Center (TORC) is a medical technology company specializing in AI-based quantitative orbital imaging and TED research. It provides contracted imaging assessment services to pharmaceutical development programs and is developing the longitudinal multimodal TED research database. Website: www.torc-research.com
BioSight Innovations provides TED treatment services, standardized clinical assessments and follow-up, including SHOEBOX Audiometry. Website: www.biosightinnovations.com
Research and Regulatory Information
The memorandum of understanding is non-binding, and the study and database remain planned initiatives. Glandy authorizations and certifications vary by product and jurisdiction; authorization outside the United States does not constitute US FDA clearance. Investigational technologies have not been established as substitutes for clinical examination or conventional audiometry.
Study activities and research data use will be subject to applicable approvals, consent and privacy safeguards. The named pharmaceutical companies do not sponsor or endorse this collaboration by virtue of their separate contractual relationships with TORC. Dr. Ugradar leads both TORC and BioSight Innovations.

